O	0	10	Preventive
O	11	20	Analgesic
O	21	29	Efficacy
O	30	32	of
B-intervention	33	40	Nefopam
O	41	43	in
B-condition	44	49	Acute
I-condition	50	53	and
I-condition	54	61	Chronic
I-condition	62	66	Pain
O	67	72	After
O	73	79	Breast
O	80	86	Cancer
O	87	94	Surgery
O	94	95	:
O	96	97	A
O	98	109	Prospective
O	109	110	,
O	111	117	Double
O	117	118	-
O	118	123	Blind
O	123	124	,
O	125	128	and
O	129	139	Randomized
O	140	145	Trial
O	145	146	.

O	147	153	Breast
O	154	160	cancer
O	161	168	surgery
O	169	171	is
O	172	177	known
O	178	180	to
O	181	186	cause
O	187	193	severe
O	194	199	acute
O	200	213	postoperative
O	214	218	pain
O	218	219	,
O	220	225	which
O	226	229	can
O	230	237	persist
O	238	241	for
O	242	243	a
O	244	248	long
O	249	253	time
O	253	254	.

O	255	257	We
O	258	270	administered
O	271	278	nefopam
O	279	291	preventively
O	292	294	to
B-eligibility	295	303	patients
I-eligibility	304	314	undergoing
I-eligibility	315	325	lumpectomy
I-eligibility	326	330	with
I-eligibility	331	339	axillary
I-eligibility	340	345	lymph
I-eligibility	346	350	node
I-eligibility	351	361	dissection
I-eligibility	362	364	or
I-eligibility	365	373	sentinel
I-eligibility	374	379	lymph
I-eligibility	380	384	node
I-eligibility	385	391	biopsy
O	391	392	,
O	393	396	and
O	397	406	evaluated
O	407	410	its
O	411	419	efficacy
O	420	422	on
O	423	428	acute
O	429	432	and
O	433	440	chronic
O	441	454	postoperative
O	455	459	pain
O	459	460	.

O	461	469	Enrolled
O	470	478	patients
O	479	483	were
O	484	492	assigned
O	493	495	to
O	496	499	the
O	500	507	nefopam
O	508	509	(
O	509	510	n
O	511	512	=
B-intervention-participants	513	515	41
O	515	516	)
O	517	519	or
O	520	523	the
B-control	524	531	control
O	532	533	(
O	533	534	n
O	535	536	=
B-control-participants	537	539	42
O	539	540	)
O	541	546	group
O	546	547	.

O	548	554	Before
O	555	565	initiating
O	566	569	the
O	570	579	operation
O	579	580	,
O	581	583	20
O	584	586	mg
O	587	589	of
O	590	597	nefopam
O	598	601	was
O	602	607	given
O	608	610	to
O	611	614	the
O	615	623	patients
O	624	626	of
O	627	630	the
O	631	638	nefopam
O	639	644	group
O	644	645	,
O	646	649	and
O	650	656	normal
O	657	663	saline
O	664	667	was
O	668	672	used
O	673	675	in
O	676	679	the
O	680	687	control
O	688	693	group
O	693	694	.

O	695	704	Ketorolac
O	705	708	was
O	709	714	given
O	715	717	at
O	718	721	the
O	722	725	end
O	726	728	of
O	729	736	surgery
O	736	737	,
O	738	741	and
O	742	751	meloxicam
O	752	755	was
O	756	766	prescribed
O	767	769	in
O	770	773	the
O	774	787	postoperative
O	788	794	period
O	795	797	to
O	798	801	all
O	802	810	patients
O	811	813	in
O	814	818	both
O	819	825	groups
O	825	826	.

O	827	831	Pain
O	832	835	was
O	836	844	assessed
O	845	850	using
O	851	852	a
O	853	862	numerical
O	863	869	rating
O	870	875	scale
O	876	877	(
O	877	880	NRS
O	880	881	)
O	881	882	,
O	883	886	and
O	887	890	the
O	891	897	rescue
O	898	907	analgesic
O	908	912	drug
O	913	916	was
O	917	922	given
O	923	927	when
O	928	931	the
O	932	935	NRS
O	936	939	was
O	940	941	>
O	941	942	5
O	942	943	.

O	944	958	Implementation
O	959	961	of
O	962	975	postoperative
O	976	988	chemotherapy
O	988	989	,
O	990	1002	radiotherapy
O	1003	1004	(
O	1004	1006	RT
O	1006	1007	)
O	1007	1008	,
O	1009	1011	or
O	1012	1019	hormone
O	1020	1027	therapy
O	1028	1031	was
O	1032	1041	evaluated
O	1041	1042	.

O	1043	1046	The
B-outcome	1047	1050	NRS
I-outcome	1051	1053	of
I-outcome	1054	1067	postoperative
I-outcome	1068	1072	pain
O	1073	1076	was
O	1077	1090	significantly
O	1091	1096	lower
O	1097	1099	in
O	1100	1103	the
O	1104	1111	nefopam
O	1112	1116	than
O	1117	1119	in
O	1120	1123	the
O	1124	1131	control
O	1132	1137	group
O	1138	1140	in
O	1141	1144	the
O	1145	1159	postanesthetic
O	1160	1164	care
O	1165	1169	unit
O	1170	1171	(
B-iv-cont-mean	1171	1172	4
I-iv-cont-mean	1172	1173	.
I-iv-cont-mean	1173	1174	5
O	1175	1176	±
B-iv-cont-sd	1177	1178	2
I-iv-cont-sd	1178	1179	.
I-iv-cont-sd	1179	1180	2
O	1181	1183	vs
B-cv-cont-mean	1184	1185	5
I-cv-cont-mean	1185	1186	.
I-cv-cont-mean	1186	1187	7
O	1188	1189	±
B-cv-cont-sd	1190	1191	1
I-cv-cont-sd	1191	1192	.
I-cv-cont-sd	1192	1193	5
O	1193	1194	,
O	1195	1207	respectively
O	1207	1208	;
O	1209	1210	P
O	1211	1212	=
O	1213	1214	0
O	1214	1215	.
O	1215	1217	01
O	1217	1218	)
O	1218	1219	,
B-outcome	1220	1222	at
I-outcome	1223	1236	postoperative
I-outcome	1237	1238	6
I-outcome	1239	1240	h
O	1241	1242	(
B-iv-cont-mean	1242	1243	3
I-iv-cont-mean	1243	1244	.
I-iv-cont-mean	1244	1245	0
O	1246	1247	±
B-iv-cont-sd	1248	1249	1
I-iv-cont-sd	1249	1250	.
I-iv-cont-sd	1250	1251	6
O	1252	1254	vs
B-cv-cont-mean	1255	1256	4
I-cv-cont-mean	1256	1257	.
I-cv-cont-mean	1257	1258	5
O	1259	1260	±
B-cv-cont-sd	1261	1262	1
I-cv-cont-sd	1262	1263	.
I-cv-cont-sd	1263	1264	3
O	1264	1265	,
O	1266	1278	respectively
O	1278	1279	;
O	1280	1281	P
O	1282	1283	<
O	1284	1285	0
O	1285	1286	.
O	1286	1289	001
O	1289	1290	)
O	1290	1291	,
O	1292	1295	and
B-outcome	1296	1298	at
I-outcome	1299	1312	postoperative
I-outcome	1313	1315	24
I-outcome	1316	1317	h
O	1318	1319	(
B-iv-cont-mean	1319	1320	3
I-iv-cont-mean	1320	1321	.
I-iv-cont-mean	1321	1322	1
O	1323	1324	±
B-iv-cont-sd	1325	1326	1
I-iv-cont-sd	1326	1327	.
I-iv-cont-sd	1327	1328	1
O	1329	1331	vs
B-cv-cont-mean	1332	1333	3
I-cv-cont-mean	1333	1334	.
I-cv-cont-mean	1334	1335	8
O	1336	1337	±
B-cv-cont-sd	1338	1339	1
I-cv-cont-sd	1339	1340	.
I-cv-cont-sd	1340	1341	5
O	1341	1342	,
O	1343	1355	respectively
O	1355	1356	;
O	1357	1358	P
O	1359	1360	=
O	1361	1362	0
O	1362	1363	.
O	1363	1365	01
O	1365	1366	)
O	1367	1371	with
O	1372	1379	reduced
O	1380	1383	use
O	1384	1386	of
O	1387	1393	rescue
O	1394	1403	analgesic
O	1404	1409	drugs
O	1409	1410	.

O	1411	1424	Significantly
O	1425	1430	fewer
O	1431	1439	patients
O	1440	1448	suffered
O	1449	1453	from
B-outcome	1454	1461	chronic
I-outcome	1462	1475	postoperative
I-outcome	1476	1480	pain
O	1481	1483	in
O	1484	1487	the
O	1488	1495	nefopam
O	1496	1500	than
O	1501	1503	in
O	1504	1507	the
O	1508	1515	control
O	1516	1521	group
O	1522	1524	at
O	1525	1538	postoperative
O	1539	1540	3
O	1541	1547	months
O	1548	1549	(
B-iv-bin-percent	1549	1551	36
I-iv-bin-percent	1551	1552	.
I-iv-bin-percent	1552	1553	6
I-iv-bin-percent	1553	1554	%
O	1555	1557	vs
B-cv-bin-percent	1558	1560	59
I-cv-bin-percent	1560	1561	.
I-cv-bin-percent	1561	1562	5
I-cv-bin-percent	1562	1563	%
O	1563	1564	,
O	1565	1566	P
O	1567	1568	=
O	1569	1570	0
O	1570	1571	.
O	1571	1573	04
O	1573	1574	)
O	1574	1575	.

O	1576	1587	Considering
O	1588	1592	only
O	1593	1596	the
O	1597	1603	cohort
O	1604	1611	without
O	1612	1625	postoperative
O	1626	1634	adjuvant
O	1635	1637	RT
O	1637	1638	,
O	1639	1642	the
O	1643	1653	difference
O	1654	1656	in
O	1657	1660	the
B-outcome	1661	1671	proportion
I-outcome	1672	1674	of
I-outcome	1675	1683	patients
I-outcome	1684	1693	reporting
I-outcome	1694	1701	chronic
I-outcome	1702	1706	pain
O	1707	1716	increased
O	1717	1718	(
B-iv-bin-percent	1718	1720	23
I-iv-bin-percent	1720	1721	.
I-iv-bin-percent	1721	1722	5
I-iv-bin-percent	1722	1723	%
O	1724	1726	in
O	1727	1730	the
O	1731	1738	nefopam
O	1739	1744	group
O	1745	1747	vs
B-cv-bin-percent	1748	1750	61
I-cv-bin-percent	1750	1751	.
I-cv-bin-percent	1751	1752	5
I-cv-bin-percent	1752	1753	%
O	1754	1756	in
O	1757	1760	the
O	1761	1768	control
O	1769	1774	group
O	1774	1775	,
O	1776	1777	P
O	1778	1779	=
O	1780	1781	0
O	1781	1782	.
O	1782	1784	04
O	1784	1785	)
O	1785	1786	.

O	1787	1797	Preventive
O	1798	1805	nefopam
O	1806	1809	was
O	1810	1817	helpful
O	1818	1820	in
O	1821	1829	reducing
O	1830	1833	the
O	1834	1839	acute
O	1840	1853	postoperative
O	1854	1858	pain
O	1858	1859	,
O	1860	1864	with
O	1865	1872	reduced
O	1873	1876	use
O	1877	1879	of
O	1880	1886	rescue
O	1887	1896	analgesic
O	1897	1902	drugs
O	1902	1903	,
O	1904	1907	and
O	1908	1910	it
O	1911	1922	contributed
O	1923	1925	to
O	1926	1933	reduced
O	1934	1944	occurrence
O	1945	1947	of
O	1948	1955	chronic
O	1956	1960	pain
O	1961	1963	at
O	1964	1977	postoperative
O	1978	1979	3
O	1980	1986	months
O	1987	1992	after
O	1993	1999	breast
O	2000	2006	cancer
O	2007	2014	surgery
O	2014	2015	.
